Protagenic Therapeutics, Inc.\new Business Combination, Separately Recognized Transactions, Liabilities Recognized
Protagenic Therapeutics, Inc.\new (PTIX) had Business Combination, Separately Recognized Transactions, Liabilities Recognized of $7.64 million as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Separately Recognized Transaction
us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsLiabilitiesRecognized · last filed 2026-08-19
- 2026-06-30: Business Combination, Separately Recognized Transactions, Liabilities Recognized $7.64M.
- 2026-03-31: Business Combination, Separately Recognized Transactions, Liabilities Recognized $7.64M.
| Period end | Business Combination, Separately Recognized Transactions, Liabilities Recognized |
|---|---|
| 2026-06-30 | $7.64M 10-Q · filed 2026-08-19 |
| 2026-03-31 | $7.64M 10-K · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |